Table 1.
Patient characteristics and baseline data at the time of enrollment in Phase 1 clinic.
| Variable | N (%)(range) |
|---|---|
| Median Age | 54.4 |
| Caucasian | 129 (80%) |
| African Americans | 32 (20%) |
| Male | 76 (47%) |
| ECOG 0 | 59 (38%) |
| Immunotherapy (IOT) | 40 (25%) |
| Targeted treatments (TT) | 122 (75%) |
| Base line Albumin | 4 (2.8–4.8) |
| Base line LDH | 190.5 (109.0–895.0) |
| Prior Rx ≤ 2 | 72 (44%) |
| Prior Rx 3–4 | 52 (32%) |
| Prior Rx ≥ 5 | 38 (24%) |
| Prior Radiation | 72 (45%) |
| Hematological malignancies | 55 (34%) |
| Non-Hematological Malignancies | 107 (66%) |
N = 162